Cargando…
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illn...
Autores principales: | Devos, Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tomé, Romano, Marta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler, Lucie, Moonen, Martial, Moutschen, Michel, Van Regenmortel, Niels, Ariën, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias M., Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, Meyfroidt, Geert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576805/ https://www.ncbi.nlm.nih.gov/pubmed/34446469 http://dx.doi.org/10.1183/13993003.01724-2021 |
Ejemplares similares
-
A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
por: Misset, Benoît, et al.
Publicado: (2020) -
Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
por: Misset, Benoît, et al.
Publicado: (2021) -
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
por: Devos, Timothy, et al.
Publicado: (2020) -
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
por: Devos, Timothy, et al.
Publicado: (2020) -
Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial
por: Gyselinck, Iwein, et al.
Publicado: (2021)